Anti-Obesity Medical Devices Market (2026-2036)

The growth of this market is mainly driven by the large and undertreated population living with obesity, the superior and durable weight loss achieved with device-based and surgical treatments, and regulatory approvals that are expanding the range of less invasive options. However, the substitution of GLP-1 medications for procedures, the commercial fragility of companies developing non-surgical devices, limited reimbursement for endoscopic and non-surgical therapies, and safety concerns and regulatory scrutiny restrain the growth of this market.

Furthermore, weight maintenance after GLP-1 discontinuation, device and drug combination therapies, and rising procedure volumes in emerging markets are expected to offer growth opportunities for the stakeholders in this market. However, demonstrating durable outcomes relative to medications and surgery, integrating devices with pharmacotherapy, generating evidence for post-medication weight maintenance, and uncertainty in procedure volumes remain major challenges impacting the growth of this market. Additionally, the evolution from surgery-only treatment to a multi-modal obesity care continuum, the rise of endoscopic and swallowable devices, the shift toward gastric bypass and revisional surgery, and the integration of digital and muscle-focused support platforms are prominent trends in this market.

The Anti-Obesity Medical Devices Market comprises medical devices used to treat obesity and to help patients achieve and maintain weight loss, either through surgery or through less invasive interventions. The market covers surgical devices used in metabolic and bariatric surgery, including staplers and reloads, energy devices, access devices, suturing devices, and robotic instruments; endoscopic devices used in endoscopic sleeve gastroplasty (ESG), duodenal mucosal resurfacing, and endoscopic liners; intragastric balloons placed endoscopically or swallowed as capsules; adjustable gastric bands; neuromodulation and electrical stimulation devices; and ingestible and oral devices that promote satiety or restrict intake. Pharmaceutical products and consumer weight-loss products without medical device status are excluded. The ecosystem spans surgical device manufacturers, endoscopy companies, specialist obesity device developers, robotic surgery companies, hospitals, ambulatory surgery centers, obesity clinics, gastroenterologists and bariatric surgeons, payers, and professional societies.

The clinical need remains vast. The World Health Organization estimated that 890 million adults were living with obesity in 2022. According to the ASMBS, 270,089 metabolic and bariatric procedures were performed in the U.S. in 2023, yet fewer than 1% of eligible patients undergo surgery in any given year, and an analysis of nearly 20 million U.S. patients with severe obesity presented at the ASMBS 2026 meeting found that 90% to 95% received no obesity treatment between 2018 and 2025. Device-based treatment delivers durable results: a study of 51,085 patients presented at the ASMBS 2025 meeting found that sleeve gastrectomy and gastric bypass produced 24% total weight loss after two years, compared with 4.7% for patients prescribed GLP-1 medications for at least six months.

GLP-1 medications have nonetheless reduced demand for many devices. U.S. procedures at accredited centers fell 23% between 2022 and 2024 to just over 177,000, according to American College of Surgeons data, and ASMBS estimates show intragastric balloon procedures in the U.S. fell from 4,358 in 2022 to 1,461 in 2023, while ESG procedures were flat at about 4,587. Non-surgical device companies have struggled: Allurion Technologies reported third-quarter 2025 revenue of USD 2.7 million, down from USD 5.4 million a year earlier, after restructuring and transitioning to distribution partners, and pivoted its strategy toward combining its balloon with low-dose GLP-1 therapy.

At the same time, the device pipeline is advancing. The FDA granted marketing authorization in July 2022 for an endoscopic suturing system specifically indicated for ESG, and granted premarket approval in February 2026 to the Allurion Gastric Balloon System, a balloon swallowed as a capsule without endoscopy or sedation, after the 550-subject AUDACITY pivotal trial. Fractyl Health completed randomization in its REMAIN-1 pivotal cohort in February 2026, testing whether its Revita duodenal mucosal resurfacing procedure can help patients maintain weight loss after stopping tirzepatide, with a potential FDA submission planned for late 2026. These developments point to a future in which devices are used alongside and after medication, rather than only as an alternative.